Schrodinger, Inc. (SDGR): Total Liabilities
$362.11M
As of 2025-12-31
$311.44M
As of 2026-06-30
+14.6%
3-year compound annual growth
+24.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $362.11M | -9.9% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $401.78M | +57.9% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $254.40M | +5.7% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $240.68M | +20.7% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $199.40M | +63.1% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $122.24M | +114.4% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $57.01M | n/a | 2021-03-04, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $362.11M | -9.9% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $284.00M | -46.4% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $543.42M | +388.1% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $34.89M | -21.3% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $509.73M | +128.3% |
| Harrow, Inc. (HROW) | 2025-12-31 | $347.39M | +8.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $343.95M | +27.5% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $85.96M | -29.1% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $369.84M | +4.9% |
Compare SDGR, ARVN, LGND, KROS side by side · Screen every company in Pharmaceutical Preparations ↗